Omega Therapeutics
Programmable epigenome control platform that modulates gene expression through epigenetic mechanisms
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 39 pending · first 2024
- Rank in peer group#73 of 342
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 342 peers
Line = medianBiotech · Platform
- Granted patents#73 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 40- GrantedCOMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSIONUSPTOUS 11,987,791
- PendingSubstituted Aryl Lipids And Compositions And Uses ThereofUSPTOApplication 63705230
- PendingCompositions And Methods For Increasing CXCL9 And CXCL10 Gene ExpressionUSPTOApplication 63664585
Show all 40 patent records
- COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSIONMay 21, 2024 · US 11,987,791Granted
- Substituted Aryl Lipids And Compositions And Uses ThereofApplication 63705230Pending
- Compositions And Methods For Increasing CXCL9 And CXCL10 Gene ExpressionApplication 63664585Pending
- Lipid Nanoparticles For Topical DeliveryApplication 63655260Pending
- Methods And Compositions For Modulating Methylation Of A Target GeneApplication PCTUS2024029576Pending
- Methods And Compositions For Modulating PCSK9 ExpressionApplication PCTUS2024029573Pending
- Epigenetic Modulation For Upregulation Of GenesApplication 63643712Pending
- Methods For Assessing Dosage For Epigenetic Modifying AgentsApplication 63574657Pending
- Substituted Piperazine Ionizable Lipids Useful For Therapeutic Lipid Nanoparticle (lnp) DeliveryApplication 63624550Pending
- Aryl And Heteroaryl Lipid Compounds, Lipid Nanoparticle (lnp) Formulations, And Therapeutic Uses ThereofApplication 63624073Pending
- Methods For Assessing Dosage For Epigenetic Modifying AgentsApplication 63599748Pending
- Phospholipids Containing A Heterocycle Ring Having A Tertiary Amine Or AmideApplication PCTUS2023075535Pending
- Methods For Assessing Dosage For Epigenetic Modifying AgentsApplication 63539057Pending
- Methods And Compositions For Modulating CTNNB1 ExpressionApplication 63514488Pending
- Compositions And Methods For Modulating CXCL9, CXCL10, And CXCL11 Gene ExpressionApplication 63468458Pending
- Lipids For Delivery Of Therapeutic AgentsApplication PCTUS2023067206Pending
- Methods And Compositions For Modulating Methylation Of A Target GeneApplication 63502581Pending
- Methods And Compositions For Modulating PCSK9 ExpressionApplication 63502590Pending
- Aryl And Heteroaryl Lipid Compounds, Lipid Nanoparticle (lnp) Formulations, And Therapeutic Uses ThereofApplication 63501566Pending
- Substituted Piperazine Ionizable Lipids Useful For Therapeutic Lipid Nanoparticle (lnp) DeliveryApplication 63494872Pending
- Lipid-like Substituted Aryl And Heteroaryl Compounds As Lipid Nanoparticle (lnp) Delivery Materials And Therapeutic Uses ThereofApplication 63494871Pending
- Heterocycle Ring Cationic Lipids For Delivery Of Therapeutic AgentsApplication 63380470Pending
- Lipids For Delivery Of Therapeutic AgentsApplication 63380214Pending
- Heterocycle Ring Cationic Lipids For Delivery Of Therapeutic AgentsApplication 63380218Pending
- Heterocycle Ring Cationic Lipids For Delivery Of Therapeutic AgentsApplication 63378043Pending
- Compositions And Methods For Modulating Secreted Frizzled Receptor Protein 1 (SFRP1) Gene ExpressionApplication PCTUS2022036389Pending
- Lipids For Delivery Of Therapeutic AgentsApplication 63344162Pending
- Tissue-specific Nucleic Acid Delivery By Mixed Cationic Lipid ParticlesApplication PCTUS2022025674Pending
- Tissue-specific Nucleic Acid Delivery By 1,2-DIOLEOYL-3-TRIMETHYLAMMONIUM-PROPANE (dotap) Lipid NanoparticlesApplication PCTUS2021063555Pending
- Compositions And Methods For Modulating Secreted Frizzled Receptor Protein 1 (SFRP1) Gene ExpressionApplication 63219153Pending
- Tissue-specific Nucleic Acid Delivery By Mixed Cationic Lipid ParticlesApplication 63178050Pending
- Compositions And Methods For Modulating Forkhead Box P3 (FOXP3) Gene ExpressionApplication PCTUS2021021825Pending
- Tissue-specific Nucleic Acid Delivery By 1,2-DIOLEOYL-3-TRIMETHYLAMMONIUM-PROPANE (dotap) Lipid NanoparticlesApplication 63127812Pending
- Methods And Compositions For Modulating Frataxin Expression And Treating Friedrich's AtaxiaApplication PCTUS2020052101Pending
- Compositions And Methods For Modulating Apolipoprotein B (apob) Gene ExpressionApplication PCTUS2020052119Pending
- COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4-alpha) GENE EXPRESSIONApplication PCTUS2020052275Pending
- Compositions And Methods For Modulating Forkhead Box P3 (FOXP3) Gene ExpressionApplication 62988044Pending
- Methods And Compositions For Modulating Frataxin Expression And Treating Friedrich's AtaxiaApplication 62904391Pending
- Compositions And Methods For Modulating Apolipoprotein B (apob ) Gene ExpressionApplication 62904325Pending
- Compositions And Methods For Increasing CXCL9 And CXCL10 Gene ExpressionApplication 63710739Pending
Related companies, and why
- INHIPROT, LLCSimilar federal contract value in Biotech · null in contracts
- SENSEION, LLCSimilar federal contract value in Biotech · null in contracts
- Kalaris TherapeuticsSimilar federal contract value in Biotech · null in contracts
- NuveloSimilar federal contract value in Biotech · null in contracts
- AstronauTxSimilar federal contract value in Biotech · null in contracts
- Socrates Biosciences IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .